Evidence map›Paper›PMID 40872913›Full record

ArticleVaccines2025

Integrated Analysis of the Safety Experience in Adults with the Bivalent Respiratory Syncytial Virus Prefusion F Vaccine.

Kumar Ilangovan, David Radley, Michael Patton, Emma Shittu, Maria Maddalena Lino, Christos Goulas, Kena A Swanson, Annaliesa S Anderson, Alejandra Gurtman, Iona Munjal

Abstract read
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kumar IlangovanVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.ORCID 0009-0002-0327-9265
David RadleyVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.
Michael PattonVaccine Research & Development, Pfizer Ltd., Marlow SL7 1YL, UK.
Emma ShittuVaccine Research & Development, Pfizer Ltd., Marlow SL7 1YL, UK.
Maria Maddalena LinoWorldwide Safety, Pfizer Srl, 20152 Milan, Italy.
Christos GoulasWorldwide Safety, Pfizer Hellas SA, 55535 Thessaloniki, Greece.ORCID 0009-0005-6063-6785
Kena A SwansonVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.ORCID 0000-0002-3389-8414
Annaliesa S AndersonVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.
Alejandra GurtmanVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.
Iona MunjalVaccine Research & Development, Pfizer Inc., Pearl River, NY 10965, USA.

Funding

Pfizer Inc N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clinical trialRSVRSVpreFsafetyvaccine

Identifiers

PMID40872913
PMCPMC12390091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.